Company intelligence / Profile preview
TMS Co., Ltd.
Fuchu-shi, Tokyo, Japan
- Ownership
- Private
- Employees
- ~18
- Development stage
- Other
01
Overview
Lead asset TMS-007 (JX10) demonstrated efficacy and safety in a Phase 2a study for acute ischemic stroke. TMS-007 rights were acquired (option exercised) by Biogen in 2021 for $357M milestone value, subsequently transferred to JIXING in 2024 for development/marketing in Japan. Pipeline includes preclinical and IND-stage assets for hypertension, kidney injury, and spinal cord injury.
- Therapeutic areas
- NephrologyCardiovascularNeurologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Biogen (option/agreement and acquisition of TMS-007; completed)JIXING Pharmaceuticals (current rights holder in Japan for TMS-007)RTW Investments LP (major institutional investor and partnership through Corxel)Ji Xing Pharmaceuticals Limited (strategic alliance)Hokkaido UniversityKanazawa University (academic collaborations)Teikyo University (joint research on renal biomarkers)
Beyond the preview
Go deeper on TMS Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMS Co., Ltd..